Internal Medicine, Rheumatology · Tifton, GA
NPI
1720195837
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2227 US Highway 41 N
Tifton, GA, 31794
Phone (229) 391-3320
Groups this clinician bills Medicare through
Medicare paid, 2024
$199K
11,624 services
Medicare patients, 2024
445
Average age 72
Drug cost, 2024
$9.4M
9,661 prescriptions
Company payments, 2025
$259K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James E Mossell III was code J0897 (injection, denosumab, 1 mg), 3,181 times for 50 patients. In total James E Mossell III billed 11,624 services in 32 codes, and Medicare paid $199K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-12-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,181 | 50 | $19.34 | $62K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,480 | 23 | $0.10 | $148 |
| 99214 Office E&M - Established | Office | 873 | 422 | $75.90 | $66K |
| 36415 Venipuncture Blood Collection | Office | 308 | 240 | $8.46 | $2,605 |
| 96372 Injection Administration | Office | 154 | 88 | $8.96 | $1,380 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 132 | 23 | $0.69 | $91.12 |
| 20611 Joint Injection | Office | 93 | 57 | $69.17 | $6,432 |
| 99215 Office E&M - Established | Office | 39 | 33 | $101.75 | $3,968 |
| 99205 Office E&M - New | Office | 20 | 20 | $125.27 | $2,505 |
| 99204 Office E&M - New | Office | 13 | 13 | $117.59 | $1,529 |
By year: 2022 $225K for 10,579 services; 2023 $228K for 10,149 services; 2024 $199K for 11,624 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 308 | 240 | $8.46 | $2,605 |
Medicare prescription drug claims, 2024
In 2024, the drug James E Mossell III prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 975 prescriptions and refills. In total James E Mossell III wrote 9,661 Medicare prescriptions that cost $9.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 975 | 1,464 | 216 | $33K |
| Gabapentin Generic | 561 | 855 | 139 | $9,079 |
| Allopurinol Generic | 520 | 912 | 119 | $3,675 |
| Prednisone Generic | 445 | 576 | 102 | $2,400 |
| Pregabalin Generic | 399 | 469 | 75 | $7,908 |
| Alendronate Sodium Generic | 329 | 520 | 74 | $1,898 |
| Methotrexate Methotrexate Sodium | 321 | 485 | 83 | $4,034 |
| Tramadol Hcl Generic | 306 | 306 | 82 | $2,006 |
| Leflunomide Generic | 304 | 475 | 84 | $13K |
| Duloxetine Hcl Generic | 277 | 390 | 56 | $3,673 |
| Celecoxib Generic | 210 | 273 | 55 | $3,653 |
| Levothyroxine Sodium Generic | 195 | 340 | 44 | $2,020 |
| Meloxicam Generic | 190 | 304 | 57 | $834 |
| Humira(Cf) Pen Adalimumab | 171 | 171 | 26 | $1.8M |
| Colchicine Generic | 165 | 229 | 39 | $13K |
Brand drugs: 1,395 claims; generic drugs: 8,252 claims; opioid claims: 404.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James E Mossell III $259K ($259K in general payments such as food, travel and fees) from 25 companies. The largest payer was Amgen Inc. with $82K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 134 | $82K |
| Abbvie Inc. ABBV | 88 | $57K |
| UCB, Inc. UCB.BR | 60 | $36K |
| GlaxoSmithKline, LLC. GSK | 29 | $26K |
| ANI Pharmaceuticals, Inc. ANIP | 42 | $21K |
| Genzyme Corporation SNY | 20 | $14K |
| Mallinckrodt Hospital Products Inc. | 20 | $9,701 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 16 | $5,897 |
| Sobi, Inc SOBI.ST | 4 | $2,640 |
| Janssen Biotech, Inc. JNJ | 9 | $2,527 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.